MMR's hub-and-spoke PET-CT diagnostic chain — 90% revenue growth with 32% EBITDA margins

Invicta Diagnostic Limited operates a hub-and-spoke diagnostic chain across MMR under brand 'PC Diagnostics'. 7 centres + 1 centralized lab offering PET-CT, MRI, CT, pathology, and teleradiology. Revenue doubled in FY25 to ₹30.10 Cr with 31.8% EBITDA margins and strong OCF (1.33x PAT). Now expanding beyond MMR via Vinchurkar Diagnostics acquisition (Nashik, 30-year brand). Listed NSE Emerge December 2025. Operates in ₹1,055B Indian diagnostic market growing at 10.4% CAGR.

Invicta Diagnostic Limited (CIN: U86100MH2023PLC414723) traces its origins to Invicta Diagnostic LLP, incorporated on January 22, 2021 (LLPIN: AAV-5564). The LLP was converted to a private limited company on December 1, 2023, and then to a public limited company on April 20, 2024 — moving rapidly from inception to public listing in under 4 years. The company operates under the brand 'PC Diagnostics' and has built a network of 7 diagnostic centres plus 1 centralized lab across the Mumbai Metropolitan Region. The flagship hub in Thane houses PET-CT, MRI, and CT scan capabilities — PET-CT being a rare offering among SME diagnostic chains, typically used for cancer staging and monitoring. Additional hubs in Marol, Wadala, and Mira-Bhayender offer MRI and CT capabilities, while spoke centres in Sewri, Kalwa, and Byculla serve as sample collection and basic diagnostics points feeding into the hub labs. The business model is dual-channel: B2B (referrals from hospitals, clinics, and individual practitioners) and B2C (direct walk-in patients). Revenue mix skews towards radiology services (PET-CT, MRI, CT scans) which carry higher ticket sizes and margins compared to pathology and clinical lab tests. A significant strategic pivot occurred in early 2026 when the company's Board approved variation in IPO objects to allocate ₹7.60 Cr for acquiring up to 95% of Vinchurkar Diagnostics Pvt Ltd — a 30-year-old diagnostic brand in Nashik. The first tranche (51% stake) was completed on May 8, 2026, with the remaining 44% to follow. Simultaneously, the company incorporated 3 new LLPs (Porteus Medical, Shegaon Diagnostic, and others) to establish centres in Pune, Shegaon/Akola, and additional Maharashtra locations.

India's diagnostic market: ₹1,055 billion (CY2024), 10.4% CAGR. Pathology 62% / Radiology 38% — radiology growing faster (11.5% vs 9.7%). 80-83% unorganized; only 2,150 of 108,000 labs NABL accredited (2%). Maharashtra: ₹3,550 Cr market, 292 NABL labs (leading state). Key drivers: aging population (65+ at 7.1%), lifestyle diseases (diabetes 17%), health insurance penetration (AB-PMJAY 40%), post-COVID preventive health awareness. Healthcare spending targeted at 2.5% GDP by 2025.

Competes against national chains (Dr. Lal PathLabs 280+ labs, Metropolis 200+ labs, Agilus/SRL, Thyrocare) and regional players (Aspira Pathlab, LordsMed). Differentiation: radiology focus with PET-CT rare among SME chains. Equipment barriers (PET-CT ₹15-25 Cr) and AERB licensing create regulatory moats. Vulnerability: small scale vs national chains' deeper pockets and networks.

Authorized: ₹12 Cr. Paid-up: ₹841.79 Lakhs (84,17,920 shares). Post-IPO: ~1,17,26,720 shares. Net Worth: ₹13.60 Cr. D/E: ~0.26x. LT Borrowings: ₹353.84L. No contingent liabilities.

Hub-and-spoke network across MMR: Thane flagship (PET-CT/MRI/CT), Marol (MRI/CT), Wadala (PET-CT/CT), Mira-Bhayender (MRI/CT), Byculla (MRI/CT) as hubs. Sewri, Kalwa as spokes. Lower Parel centralized lab. Equipment gross block ₹20.36 Cr. 6 subsidiary LLPs as operating vehicles. Employee costs ₹4.81 Cr (125% YoY increase for staffing). B2B (hospital referrals) + B2C (walk-ins) dual channel.

Not applicable — diagnostic services operate per-test. Revenue visibility from equipment utilization, referral networks, walk-in volumes, and Vinchurkar acquisition adding Nashik volumes.

Revenue nearly doubled in FY25 to ₹30.10 Cr (90.1% growth). Subsidiary operations contributed ~46% of consolidated revenue. EBITDA margins normalized from ~45% to ~32% — healthy for diagnostics. PAT grew 29.6% to ₹4.93 Cr. OCF exceeded PAT at ₹6.56 Cr (1.33x ratio). D/E conservative at ~0.26x. Healthcare GST-exempt.

NSE EMERGE listed — lighter governance. Board: 4 directors (2 promoter non-exec, 2 independent). WTD Finance March 2026. Auditor: Kanak Rathod & Co — clean reports. 16 EGM resolutions passed unanimously. IPO object variation within 4 months is primary concern. No contingent liabilities.